Search

Your search keyword '"Frattegiani, Alessandro"' showing total 10 results
Start Over Author "Frattegiani, Alessandro"
10 results on '"Frattegiani, Alessandro"'

3. Phase I and II trial on infusional 5-fluorouracil and gefitinib in combination with preoperative radiotherapy in rectal cancer: 10-years median follow-up

Author

Gambacorta, Maria Antonietta, De Paoli, Antonino, Lupattelli, Marco, Chiloiro, Giuditta, Solazzo, Angela Pia, Barbaro, Brunella, Alfieri, Sergio, Vecchio, Fabio Maria, Lenkowicz, Jacopo, Navarria, Federico, Palazzari, Elisa, Bertola, Giulio, Frattegiani, Alessandro, Minsky, Bruce, and Valentini, Vincenzo

Published
2018
Full Text
View/download PDF

6. A comparative plan analysis: Constant and variable dose rate VMAT and Step-and-Shoot IMRT in head and neck cancer

Author

Tarducci Roberto, Panizza Moira Bianca, Zucchetti Claudio, Didona Annamaria, Frattegiani Alessandro, and Aristei Cynthia

Subjects
Step and shoot, business.industry, medicine.medical_treatment, Head and neck cancer, Biophysics, General Physics and Astronomy, General Medicine, Dose distribution, medicine.disease, Plan analysis, Radiation therapy, Medicine, Radiology, Nuclear Medicine and imaging, Dose rate, Nuclear medicine, business, Head and neck, Homogeneity index
Abstract

Introduction IMRT is recognized as a powerful technique to improve quality of dose distribution in head and neck (HN) radiotherapy. Purpose To compare Constant and Variable Dose Rate VMAT (CDR,VDR respectively) to Step-and-Shoot IMRT (SS CDR and VDR plans consisted of two 6 MV arcs (182° to 178°; clockwise and counterclockwise direction). All plans were performed with Pinnacle3 TPS (v 9.8). Dose distributions were compared by evaluating PTVs’ D mean , D 2% , D 50% , D 98% and Homogeneity Index (HI); for MA, SC, BS D 2% ; for PA, SG, ES, LA and TH D mean and a number of different dose-volume data in V 20 Gy – V 50 Gy range. To compare efficiency, MUs and treatment delivery time were evaluated. Results Concerning PTVs coverage, all techniques were equivalent although VMAT ones significantly improved HI and decreased D 2% . For OARs significantly better results were found for VMAT techniques with reduction in the volume of LA, TH and ES receiving medium and high doses. Compared with S&S-IMRT, VMAT techniques reduced delivery times although MUs were higher. Conclusion VMAT techniques offer better results and CDR is an additional option of rotational arc radiotherapy for linacs without variable dose rate with a lower cost.

Published
2016
Full Text
View/download PDF

7. Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II Trial (1839IL/0092)

Author

Valentini, Vincenzo, De Paoli, A, Gambacorta, Maria Antonietta, Mantini, Giovanna, Ratto, Carlo, Vecchio, Fabio Maria, Barbaro, Brunella, Innocente, R, Rossi, Concettina, Boz, G, Barba, Maria Cristina, Frattegiani, Alessandro, Lupattelli, M, Doglietto, Giovanni, Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Mantini, Giovanna (ORCID:0000-0001-5303-4499), Ratto, Carlo (ORCID:0000-0002-0556-0037), Vecchio, Fabio Maria (ORCID:0000-0002-9197-2264), Barbaro, Brunella (ORCID:0000-0002-9638-543X), Doglietto, Giovanni (ORCID:0000-0002-7394-768X), Valentini, Vincenzo, De Paoli, A, Gambacorta, Maria Antonietta, Mantini, Giovanna, Ratto, Carlo, Vecchio, Fabio Maria, Barbaro, Brunella, Innocente, R, Rossi, Concettina, Boz, G, Barba, Maria Cristina, Frattegiani, Alessandro, Lupattelli, M, Doglietto, Giovanni, Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Mantini, Giovanna (ORCID:0000-0001-5303-4499), Ratto, Carlo (ORCID:0000-0002-0556-0037), Vecchio, Fabio Maria (ORCID:0000-0002-9197-2264), Barbaro, Brunella (ORCID:0000-0002-9638-543X), and Doglietto, Giovanni (ORCID:0000-0002-7394-768X)

Abstract

To report the final data of a Phase I and II study (1839IL/0092) on the combination of an anti-epidermal growth factor receptor drug (gefitinib), infusional 5-fluorouracil, and preoperative radiotherapy in locally advanced, resectable rectal cancer.

Published
2008

8. Infusional 5-Fluorouracil and ZD1839 (Gefitinib–Iressa) in Combination With Preoperative Radiotherapy in Patients With Locally Advanced Rectal Cancer: A Phase I and II Trial (1839IL/0092)

Author

Valentini, Vincenzo, primary, De Paoli, Antonino, additional, Gambacorta, Maria Antonietta, additional, Mantini, Giovanna, additional, Ratto, Carlo, additional, Vecchio, Fabio Maria, additional, Barbaro, Brunella, additional, Innocente, Roberto, additional, Rossi, Carlo, additional, Boz, Giovanni, additional, Barba, Maria Cristina, additional, Frattegiani, Alessandro, additional, Lupattelli, Marco, additional, and Doglietto, Giovan Battista, additional

Published
2008
Full Text
View/download PDF

10. Statins Protect Against Acute RT-related Rectal Toxicity in Patients with Prostate Cancer: An Observational Prospective Study.

Author

Palumbo I, Matrone F, Montesi G, Bellavita R, Lupattelli M, Saldi S, Frattegiani A, Arena E, Mariucci C, Falcinelli L, Bini V, and Aristei C

Subjects
Aged, Aged, 80 and over, Dose Fractionation, Radiation, Humans, Male, Middle Aged, Prospective Studies, Prostate-Specific Antigen blood, Prostatic Neoplasms drug therapy, Radiometry, Radiotherapy, Intensity-Modulated methods, Risk Factors, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Prostatic Neoplasms radiotherapy, Radiation Injuries prevention & control, Rectum radiation effects
Abstract

Aim: To analyze risk factors for acute rectal toxicity during hypofractionated intensity-modulated radiotherapy (IMRT) for prostate cancer., Patients and Methods: A total of 195 patients received 74.25 Gy in 33 fractions to the prostate and, if involved, to the seminal vescicles (SV). When the risk of SV involvement was >15% according to the Roach's formula, they received 62 Gy in 33 fractions. Overall, 107/195 patients (54.87%) received hormonal therapy (luteinizing hormone-releasing hormone analogue, anti-androgen, or both). Common Terminology Criteria for Adverse Events version 3.0 was used to classify rectal toxicity., Results: Acute rectal toxicity occurred in 79 (40.51%) patients (grade 1 in 44). In univariate analysis, use of calcium channel blockers significantly reduced the acute rectal toxicity rate and 3-hydroxy-methylglutaryl CoA reductase inhibitors (statins) significantly reduced the rectal toxicity rate and grade. In multivariate analysis, only statin use was an independent protective factor., Conclusion: In patients with prostate cancer treated with a moderate hypofractionated IMRT schedule, use of statins lowered the incidence and grade of acute rectal toxicity., (Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results